迪高替尼软膏不同版本一盒的最新价格公布

Digotinib ointment is a topical JAK inhibitor used to treat atopic dermatitis. It has not yet been approved for marketing in mainland China. The main circulating version of this drug is a Japanese original drug, available in two concentration specifications of 0.25% and 0.5%, both packaged in 5g/tube and 10 tubes/box. The price of 0.25% specification is about US$96 per box, and the price of 0.5% specification is about US$130 per box. Since it is not on the market in the country, the drug cannot currently be reimbursed by medical insurance, and patients need to purchase it at their own expense.

The latest prices for a box of different versions of Digotinib ointment

It is a new type of atopic dermatitis treatment drug. Its price varies depending on the concentration and specifications. Understanding the specific price information can help patients make a good medication budget.

Price of 0.25% concentration specification

A 5-gram package of 0.25% concentration Digotinib ointment is priced at about US$96 in a box of 10. This concentration is suitable for patients with mild to moderate atopic dermatitis and can be used 1-2 times a day.

Price of 0.5% concentration specification

The price of 5g single tube of 0.5% concentration Digotinib ointment is about US$130 for a box of 10 tubes. Higher concentrations are suitable for moderate to severe patients, and the frequency of use needs to be adjusted according to medical advice.

The price may fluctuate due to purchasing channels, exchange rate fluctuations and other factors. It is recommended to obtain the latest quotation through formal channels.

Domestic marketing status of Digotinib Ointment

Currently, Digotinib Ointment has not yet received marketing approval from the China State Food and Drug Administration, and there are certain restrictions on domestic patients’ access to the drug.

Domestic approval progress

As of now, Digotinib ointment is still in the clinical trial or approval stage in China, and domestic patients are temporarily unable to obtain the drug through regular medical institutions.

Purchase channel selection

Patients in need can obtain the original Japanese version through cross-border medical platforms or overseas drug purchases, but they must pay attention to the authenticity of the drug and transportation and storage conditions.

It is recommended to wait for official approval before purchasing through formal channels to avoid being deceived and buying fake medicines.

Reimbursement status of Digotinib Ointment by medical insurance

Since it is not marketed in China, Digotinib Ointment is currently not eligible for medical insurance reimbursement, and patients need to bear all treatment costs.

Current status of medical insurance coverage

Digotinib ointment has not yet been included in China’s medical insurance catalog, and all related costs must be paid by the patient, including drug costs and possible cross-border transportation costs.

Possibility of future reimbursement

If the drug is approved for marketing in China in the future, it may first be covered by commercial insurance, and then be considered for inclusion in the medical insurance catalog based on the situation.

Alternative treatment options

Other JAK inhibitors or traditional therapies currently on the market in China may be partially reimbursed by medical insurance, and patients can consult their doctors to choose suitable alternatives.

Medication selection should comprehensively consider efficacy, safety and economic burden, and formulate a personalized treatment plan under the guidance of professional physicians.